CTI BioPharma Announces Completion of Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia

SEATTLE, March 31, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has completed a rolling New Drug Application ( " NDA " ) submission to the U.S. Food and Drug Administration ( " FDA " ) seeking...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news